Clinical Trial

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Name: Study of GV20-0251 in Participants With Solid Tumor Malignancies — clinical trial record (NCT07070518)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2025-07-16; most recent amendment 2025-12-01.

Trial Details

NCT Number	NCT07070518
Lead Sponsor	GV20 Therapeutics
Conditions	Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Non-Small Cell Lung Cancer, Melanoma, HCC - Hepatocellular Carcinoma +1 more
Enrollment	350 participants
Start Date	2025-07-11
Primary Completion	2027-07-16 (estimated)
Study Completion	2028-09-16 (estimated)
Updated on ClinicalTrials.gov	2025-12-03